Skip to main
AKTS

AKTS Stock Forecast & Price Target

AKTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aktis Oncology is projected to continue advancing its pipeline and drive growth, with potential upcoming catalysts such as dose escalation results from Phase 1b trials for its lead programs expected in early 2027 and commencement of IND-enabling studies for earlier stage programs. Their financial results for 2025 showed a wider net loss than estimated, but with ample resources to fund operations into 2029. While risks such as negative clinical results and competitive pressures exist, with adjusted operating expenses and a strong pipeline, I maintain my Buy rating and increased my 12-month price target to $33 per share.

Bears say

Aktis Oncology is facing several challenges, including competition from other companies presenting data on their B7H3- or NECTIN-4-targeted ADCs at a recent conference, which may hinder the success of its own RCT in development. Additionally, while the imaging and dosimetry results for AKY-2519 support its clinical development, the company's pipeline and potential for revenue generation are still highly dependent on the success of this lead asset. Lastly, the company's high valuation and potential dilution risk pose further concerns for investors.

AKTS has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aktis Oncology Inc (AKTS) Forecast

Analysts have given AKTS a Buy based on their latest research and market trends.

According to 4 analysts, AKTS has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aktis Oncology Inc (AKTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.